Table 1 Characteristics of Chinese breast cancer patients screened for TP53 mutations
From: Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients
| Â | Mutation Negative | % | TP53+ | % | Total | % | P-value |
|---|---|---|---|---|---|---|---|
N = 2488 | N = 20 | N = 2508 | (Wilcoxon rank sum test/Fisher Exact Test) | ||||
Mean/Median age at Diagnosis | 45.74/44 |  | 31.65/30 |  | 45.63/44 |  | < 0.001 |
Age range | 18–95 |  | 18–47 |  | 18–95 |  |  |
Bilateral cases | 439 | 17.64% | 12 | 60.00% | 451 | 17.98% | < 0.001 |
Age at breast cancer diagnosis | |||||||
  ≤ 29 | 116 | 4.66% | 9 | 45.00% | 125 | 4.98% | < 0.001 |
 30–39 | 637 | 25.60% | 6 | 30.00% | 643 | 25.64% | |
 40–49 | 998 | 40.11% | 5 | 25.00% | 1003 | 39.99% | |
  ≥ 50 | 737 | 29.62% | 0 | 0.00% | 737 | 29.39% | |
Family history of breast cancer (in first and second degree relatives) | |||||||
 Yes | 917 | 36.86% | 5 | 25.00% | 922 | 36.76% | 0.355 |
 No | 1571 | 63.14% | 15 | 75.00% | 1586 | 63.24% | |
Family history of > =3 different types of cancers (in first and second degree relatives) | |||||||
 Yes | 465 | 18.69% | 8 | 40.00% | 473 | 18.86% | 0.038 |
 No | 2023 | 81.31% | 12 | 60.00% | 2035 | 81.14% | |
Histologya | |||||||
|  | N = 2927 | N = 32 | N = 2959 |  | |||
 Ductal | 1991 | 71.21% | 17 | 58.62% | 2008 | 71.08% | 0.283 |
 Lobular | 94 | 3.36% | 1 | 3.45% | 95 | 3.36% | |
 DCIS | 498 | 17.81% | 9 | 31.03% | 507 | 17.95% | |
 Others | 213 | 7.62% | 2 | 6.90% | 215 | 7.61% | |
 Unclassified | 131 | – | 3 | – | 134 | – | |
Molecular subtypesa (excluded in-situ CA) | |||||||
|  | N = 2429 | N = 23 | N = 2452 |  | |||
 Hormone receptor + | 1744 | 75.40% | 16 | 76.19% | 1760 | 75.41% | 0.291 |
 Hormone receptor - | 36 | 1.56% | 0 | 0.00% | 36 | 1.54% | |
 HER2+ | 207 | 8.95% | 4 | 19.05% | 211 | 9.04% | |
 TNBC | 326 | 14.09% | 1 | 4.76% | 327 | 14.01% | |
 Unclassified | 116 | – | 2 | – | 118 | – | |